Article citationsMore>>

D’Haens, G., Peyrin‐Biroulet, L., Marks, D.J.B., Lisi, E., Liefaard, L., Beaton, A., et al. (2023) A Randomised, Double‐Blind, Placebo‐Controlled Study of the LAG‐3‐Depleting Monoclonal Antibody GSK2831781 in Patients with Active Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 58, 283-296.
https://doi.org/10.1111/apt.17557

has been cited by the following article:

• TITLE: Research Progress of T-Cell Immunoglobulin and Mucin Domain-Containing Protein-3 (Tim-3) in Respiratory Diseases

  AUTHORS: Qian Zhang, Chengxuan Tian, Yaowei Wang, Wei Wu

  KEYWORDS: COPD, Tim-3, Asthma, Lung Cancer

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.3, March 25, 2025

  ABSTRACT: T-cell immunoglobulin and mucin domain-containing protein-3 (Tim-3), an emerging immune checkpoint molecule, was found to critically regulate the pathogenesis of respiratory disorders, including chronic obstructive pulmonary disease (COPD), bronchial asthma, and bronchogenic carcinoma, through its dynamic expression patterns and genetic polymorphisms. This review synthesized current knowledge on the structural and functional characteristics of Tim-3, delineated its roles in COPD, asthma, and lung cancer, and evaluated its therapeutic potential, thereby offering novel perspectives for targeting Tim-3 in respiratory disease management.